Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

January 11, 2023

1 minute read

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

The Latest Analyst Ratings for Braze

May 18, 1:02 PM

Over the past 3 months, 7 analysts have published their opinion on Braze (NASDAQ:BRZE) stock. These analysts are…

August 11, 9:14 AM

BMO Capital analyst Andrew Strelzik maintains Wendy's (NASDAQ:WEN) with a Market Perform and raises the price target from $18 to $20.

August 3, 9:01 AM

Within the last quarter, Remitly Global (NASDAQ:RELY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

February 1, 5:41 AM

Keybanc analyst Justin Patterson maintains Spotify Technology (NYSE:SPOT) with a Overweight and raises the price target from $125 to $140.